This website is intended for UK healthcare professionals only Log in | Register

Tag Archives: hypertension

October 2023 Br J Cardiol 2023;30:138 doi:10.5837/bjc.2023.033

Share The Pressure

Michaela Nuttall, Mark Cobain, Shaantanu Donde, Joanne Haws

Abstract

Introduction High blood pressure (BP) is a major risk factor for reduced healthy life-expectancy and unhealthy ageing. While it is fundamentally treatable, it is currently not optimally managed. To meet national public health targets, patients must play an active role in their decisions about how best to manage their own BP through lifestyle change and drug treatment.1,2 This paper summarises ‘Share The Pressure’ (STP), a project that developed and piloted a scalable model for engaging patients on the benefits of risk factor control for healthy ageing; training healthcare professionals (HCPs) in cardiovascular disease (CVD) risk communica

| Full text

August 2023 Br J Cardiol 2023;30:83–5 doi:10.5837/bjc.2023.023

The delusion of measuring blood pressure

Gloria Hong, Breanna Hansen, Martha Gulati

Abstract

Measurement Blood pressure measurement is a quintessential part of healthcare, and accurate measurement is paramount for proper diagnosis and treatment of hypertension. However, studies indicate that inaccuracies in blood pressure monitoring are prevalent, even among healthcare professionals.2–5 Flawed measurement techniques, such as relying on a single reading, insufficient time for measurement, and incorrect arm positioning contribute to misdiagnoses. Our prior work has highlighted the inadequate adherence to accurate blood pressure measurement protocols among healthcare professionals, including even cardiologists.2 Key factors contribut

| Full text
BCS 2023: future-proofing cardiology for the next 10 years

August 2023 Br J Cardiol 2023;30:86–9

BCS 2023: future-proofing cardiology for the next 10 years

J. Aaron Henry

Abstract

What is the future of cardiovascular health? NHS Medical Director Professor Sir Stephen Powis opened the conference by outlining the growing need to provide high quality cardiovascular care. With a quarter of deaths in England attributable to cardiovascular disease and a wider cost to the economy of £15.8 billion per year,1 there is an urgent need for innovative care pathways and new technologies. He showcased virtual wards as one example of innovation, with over 100,000 patients having been managed remotely in 2022.2 In Liverpool, a Telehealth team has successfully utilised a medical monitoring app to manage patients at home, leading to a 1

| Full text

March 2020 Br J Cardiol 2020;27:37–40 doi:10.5837/bjc.2020.009

Progestogen-only pill associates with false-positive aldosterone/renin ratio screening test

Alexander Birkinshaw, Pankaj Sharma, Thang S Han

Abstract

Case presentation A 20-year-old woman was being investigated privately for syncope in May 2017. Tilt-test showed that on standing, her heart rate increased by 30 beats/minute from baseline. She was referred to the cardiology team. Her body mass index (BMI) was 23 kg/m2 and average 24-hour ambulatory blood pressure was 141/79 mmHg. She had a normal echocardiogram and 24-hour urinary catecholamines. The patient completed the standard treadmill test. Because of hypertension detected in this patient, aldosterone/renin ratio (ARR) was performed to screen for primary hyperaldosteronism (Conn’s disease). ARR was found to be raised at 156 (referen

| Full text

December 2018 Br J Cardiol 2018;25:159–60 doi:10.5837/bjc.2018.033

Percutaneous endovascular repair of congenital interruption of the thoracic aorta

Richard Armstrong, Kevin Walsh, David Mulcahy

Abstract

Figure 1. Transthoracic echocardiogram showing cessation of flow in the descending aorta Figure 2. Three-dimensional reconstruction of computed tomography (CT) aortogram showing interruption of thoracic aorta Case An asymptomatic 28-year-old man with an incidental finding of hypertension at a routine visa renewal medical presented to outpatients for review and further investigation. Significant radiofemoral delay was found on palpation of pulses, and an ejection systolic murmur heard over the praecordium. Blood pressure was recorded as 190/70 mmHg, despite therapy including irbesartan 300 mg, amlodipine 5 mg and atenolol 50 mg. Transthoracic

| Full text
Optimising cardiovascular risk reduction in diabetes

September 2018 Br J Cardiol 2018;25(suppl 2):S19–S26 doi:10.5837/bjc.2018.s10

Optimising cardiovascular risk reduction in diabetes

W David Strain

Abstract

Introduction Throughout this supplement, there has been discussion of the epidemiology of cardiovascular disease within people with diabetes, and a focus on the management of glycaemia. Given that the majority of people with diabetes ultimately die a premature cardiovascular death, diabetes management has become synonymous with cardiovascular risk reduction. However, since the United Kingdom Prospective Diabetes Study (UKPDS),1 it has become increasingly clear that the multi-factorial nature of diabetes requires a multi-factorial approach. Initially, much of this was extrapolated from existing cardiovascular data, with diabetes just being re

| Full text

July 2018 Br J Cardiol 2018;25:111–4 doi:10.5837/bjc.2018.021

Hypertension in pregnancy as the most influential risk factor for PPCM

Hawani Sasmaya Prameswari, Triwedya Indra Dewi, Melawati Hasan, Erwan Martanto, Toni M Aprami

Abstract

Introduction Peri-partum cardiomyopathy (PPCM) is an idiopathic cardiomyopathy with symptoms and signs of heart failure, secondary to disorders of ventricular systolic function, in late pregnancy or postpartum, where no other cause of heart failure is found. PPCM is one of the main causes of maternal death worldwide. Data in the US show the incidence of PPCM reaches one in 2,500 to 4,000 pregnancies, while data on the incidence in Indonesia are still unknown. Data from the 2012 IDHS (Indonesian Demographic and Health Survey) showed heart failure, including PPCM, as the cause of a high maternal mortality rate in Indonesia reaching 228 per 100,

| Full text

June 2018 Br J Cardiol 2018;25:77–80 doi:10.5837/bjc.2018.017

‘Normal’ blood pressure: too good to be true? Case series on postural syncope and the ‘white-coat’ effect

Haqeel A Jamil, Noman Ali, Mohammad Waleed, Yvonne Blackburn, Caroline Moyles, Christopher Morley

Abstract

Introduction Essential or primary hypertension (HTN), defined as an office blood pressure (BP) ≥140/90 mmHg with no identifiable cause, is a well-documented risk factor for cardiovascular disease, and the most common cardiovascular condition to be seen in primary care.1 It also represents the strongest single modifiable risk factor with regards to future morbidity and mortality.2,3 As such, current guidelines advocate pharmacological treatment if lifestyle measures are insufficient. The National Institute for Health and Care Excellence (NICE) clinical guideline for the treatment of HTN recommends step 1 treatment with an angiotensin-convert

| Full text

November 2017 Br J Cardiol 2017;24:130

New series on insights from the Bradford Healthy Hearts project

BJC Staff

Abstract

The initiative was launched in February 2015 and in a relatively short period of time, the project achieved success in all three areas with measurable improvement in outcomes, including a reduction in hospitalisations. Over 24 months, there have been around 21,000 clinical interventions, with the emphasis being on delivering change at scale, whilst being fastidious about minimising any extra workload on primary care. In this period, 13,000 patients either started statins or had their statins changed, more than 1,000 patients with atrial fibrillation were anticoagulated, and more than 5,200 hypertensive patients reached a blood pressure targe

| Full text

August 2017 Br J Cardiol 2017;24:95–6

General news

BJCardio Staff

Abstract

Improvements in patient care mean hundreds more people are surviving heart failure, a new independent study has found. The latest report from the National Heart Failure Audit (April 2015– March 2016) (link below) has found that the mortality rate for people admitted to hospital with heart failure has dropped from 9.6% the previous year to 8.9%. The reduction in the mortality rate means that in the region of 500 lives have been saved in the past year compared to 2014–15. An assessment of patients admitted to hospital with heart failure at NHS Trusts also shows that more people are being provided with crucial medicines for heart disease as

| Full text

For healthcare professionals only

Add Banner

Close

You are not logged in

You need to be a member to print this page.
Find out more about our membership benefits

Register Now Already a member? Login now
Close

You are not logged in

You need to be a member to download PDF's.
Find out more about our membership benefits

Register Now Already a member? Login now